Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Naderi, Ali ^a   Meyer, Michelle ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRONECTIN; FLUTAMIDE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROLACTIN INDUCED PROTEIN; PROTEIN; PROTEIN ILK1; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; CARRIER PROTEIN; CREB1 PROTEIN, HUMAN; GLYCOPROTEIN; INTEGRIN-LINKED KINASE; PIP PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOCRINE GLAND; ARTICLE; BREAST CANCER; CELL INVASION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEEDBACK SYSTEM; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL MOTION; CELL SURVIVAL; CLUSTER ANALYSIS; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD29; APOCRINE GLANDS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CLUSTER ANALYSIS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HUMANS; INTEGRINS; MICE; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84864811145     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3232     Document Type: Article

References (62)

1. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, Ellis IO. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005, 18:26-35. 10.1038/modpathol.3800255, 15332092.
2. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bieche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de The H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206. 10.1038/onc.2011.301, 3307061, 21785460.
3. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
4. Teschendorff AE, Naderi A, Barbosa-Morais NL, Caldas C. PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics 2006, 15:2269-2275.
5. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415, 16491124.
6. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010, 21:488-492. 10.1093/annonc/mdp510, 19887463.
7. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011, 24:924-931. 10.1038/modpathol.2011.54, 3128675, 21552212.
8. Niemeier LA, Dabbas DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2009, 23:205-212.
9. Banneau G, Guedj M, Macgrogan G, de Mascarel L, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010, 12:R63. 10.1186/bcr2626, 2949656, 20712882.
10. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008, 10:542-548. 2386539, 18516291.
11. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 2011, 13:154-166. 3033594, 21403841.
12. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131. 10.1016/j.ccr.2011.05.026, 3180861, 21741601.
13. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2009, 2:59. 10.1186/1755-8794-2-59, 2753593, 19747394.
14. Naderi A, Liu J. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 2010, 298:74-87. 10.1016/j.canlet.2010.06.005, 20605569.
15. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011, 13:R36. 10.1186/bcr2858, 3219199, 21457548.
16. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010, 16:62-65. 10.1097/PPO.0b013e3181ce4ae1, 20164692.
17. Leotoing L, Manin M, Monte D, Baron S, Communal Y, Lours C, Veyssiere G, Morel L, Beaudoin C. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J Mol Endocrinol 2007, 39:151-162. 10.1677/JME-07-0021, 17693613.
18. Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, Caldas C. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 2007, 67:6725-6736. 10.1158/0008-5472.CAN-06-4394, 17638883.
19. Ma XL, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616. 10.1016/j.ccr.2004.05.015, 15193263.
20. Naderi A, Meyer M, Dowhan DH. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 2012, 14:283-296. 3349255, 22577344.
21. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
22. Ensembl Genome Browser. , http://www.ensembl.org/index.html
23. Doppler W, Groner B, Ball RK. Prolactin and glucocorticoid hormones synergistically induce expression of transfected rat beta-casein gene promoter constructs in a mammary epithelial cell line. Proc Natl Acad Sci USA 1989, 86:104-108. 10.1073/pnas.86.1.104, 286412, 2643093.
24. Naderi A, Liu J, Hughes-Davies L. BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Mol Cancer 2010, 19:111.
25. Naderi A, Liu J, Bennett IC. BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 2010, 126:1596-1610.
26. Tullai JW, Chen J, Schaffer ME, Kamenetsky E, Kasif S, Cooper GM. Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells. J Biol Chem 2007, 282:9482-9491. 10.1074/jbc.M700067200, 1839957, 17277356.
27. Yu X, Miyamoto S, Mekada E. Integrin alpha 2 beta 1-dependent EGF receptor activation at cell-cell contact sites. J Cell Sci 2000, 113:2139-2147.
28. PATCH Public 1.0 Software. , http://www.gene-regulation.com/cgi-bin/pub/programs/patch/bin/patch.cgi
29. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35:605-623. 10.1016/S0896-6273(02)00828-0, 12194863.
30. Xing J, Ginty D, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996, 273:959-963. 10.1126/science.273.5277.959, 8688081.
31. Caputo E, Manco G, Mandrich L, Guardiola J. A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 2000, 275:7935-7941. 10.1074/jbc.275.11.7935, 10713110.
32. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci 2009, 66:447-459. 10.1007/s00018-008-8463-x, 18854942.
33. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. Embo J 2011, 30:3019-3027. 10.1038/emboj.2011.216, 3160190, 21701558.
34. Chen JY, Lin JR, Cimprich KA, Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol Cell 2012, 45:196-209. 10.1016/j.molcel.2011.11.023, 22206868.
35. De Cesare D, Jacquot S, Hanauer A, Sassone-Corsi P. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci USA 1998, 95:12202-12207. 10.1073/pnas.95.21.12202, 22809, 9770464.
36. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998, 273:32377-32379. 10.1074/jbc.273.49.32377, 9829964.
37. Wilson SH, Ljubimov AV, Morla AO, Caballero S, Shaw LC, Spoerri PE, Tarnuzzer RW, Grant MB. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest Ophthalmol Vis Sci 2003, 44:1704-1715. 10.1167/iovs.02-0773, 12657612.
38. Hocking DC, Sottile J, McKeown-Longo PJ. Activation of distinct alpha5beta1-mediated signaling pathways by fibronectin's cell adhesion and matrix assembly domains. J Cell Biol 1998, 141:241-253. 10.1083/jcb.141.1.241, 2132721, 9531562.
39. Berry MG, Goode AW, Puddefoot JR, Vinson GP, Carpenter R. Integrin beta1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness. Breast Cancer 2003, 10:214-219. 10.1007/BF02966720, 12955033.
40. Forsyth CB, Pulai J, Loeser RF. Fibronectin fragments and blocking antibodies to alpha2beta1 and alpha5beta1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum 2002, 46:2368-2376. 10.1002/art.10502, 12355484.
41. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006, 7:20-31. 10.1038/nrm1789, 16493410.
42. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001, 155:505-510. 10.1083/jcb.200108077, 2198863, 11696562.
43. Falcioni R, Antonini A, Nistico P, Di Stefano S, Crescenzi M, Natali PG, Sacchi A. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 1997, 236:76-85. 10.1006/excr.1997.3695, 9344587.
44. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, Halmos B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010, 31:577-586. 10.1093/carcin/bgq020, 2847094, 20097731.
45. Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. Embo J 2011, 30:3885-3894. 10.1038/emboj.2011.340, 21934649.
46. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Janne OA. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. Embo J 2011, 30:3962-3976. 10.1038/emboj.2011.328, 21915096.
47. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631. 10.1016/j.bcp.2006.05.017, 16846592.
48. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res 2008, 6:1544-1553. 10.1158/1541-7786.MCR-08-0189, 18922970.
49. Pagani A, Sapino A, Eusebi V, Bergnolo P, Bussolati G. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows Arch 1994, 425:459-465.
50. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 2007, 22:1221-1230.
51. Nonami Y, Hisa S, Yamamoto A, Sasaguri S, Kiyoku H, Kurumaya H. Immunohistochemical study with antibody to glycoprotein GCDFP-15 for metastatic lung cancer from breast cancer. J Cardiovasc Surg (Torino) 2001, 42:561-564.
52. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
53. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Biol Cell 2002, 22:2871-2881.
54. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001, 2:599-609. 10.1038/35085068, 11483993.
55. Myal Y, Robinson DB, Iwasiow B, Tsuyuki D, Wong P, Shiu RP. The prolactin-inducible protein (PIP/GCDFP-15) gene: cloning, structure and regulation. Mol Cell Endocrinol 1991, 80:165-175. 10.1016/0303-7207(91)90153-J, 1955075.
56. Carsol JL, Gingras S, Simard J. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. Mol Endocrinol 2002, 16:1696-1710. 10.1210/me.16.7.1696, 12089361.
57. Baniwal SK, Little GH, Chimge NO, Frenkel B. Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 2012, 227:2276-2282. 10.1002/jcp.22966, 21809344.
58. Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene 2011, doi:10.1038/onc.2011.591.
59. Murphy LC, Tsuyuki D, Myal Y, Shiu RP. Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D. J Biol Chem 1987, 262:15236-15241.
60. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007, 67:684-694. 10.1158/0008-5472.CAN-06-3166, 17234779.
61. Kuwada SK, Li X. Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol Biol Cell 2000, 11:2485-2496. 14934, 10888683.
62. Hauzenberger D, Bergstrom SE, Klominek J, Sundqvist KG. Spectrum of extracellular matrix degrading enzymes in normal and malignant T lymphocytes. Anticancer Res 1999, 19:1945-1952.